I Sens Inc

I Sens Inc's capital structure shows a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.55, suggesting it can cover its short-term liabilities with its current assets. However, the company's free cash flow is negative at -20,719,926,880 KRW, and capital expenditures are significant at -28,457,963,250 KRW, indicating ongoing investment in long-term assets. Profitability metrics for I Sens Inc are weak, with a return on equity of -1.63% and a return on assets of -0.89%. These figures are below the industry median for medical equipment and supplies, which typically exhibit positive returns. The company's operating income is modest at 550,807,390 KRW, and it reported a net loss of 5,148,914,770 KRW, highlighting significant challenges in achieving profitability. Geographically, I Sens Inc's revenue is concentrated in South Korea, with no disclosed international operations. The company's business is primarily driven by domestic healthcare demand, which exposes it to local economic and regulatory conditions. There are no disclosed segments beyond the core medical equipment and supplies business, and the company does not report revenue by geographic region. The company's growth trajectory is mixed. While revenue for the latest period is reported at 315,444,741,610 KRW, the net loss and negative free cash flow suggest operational inefficiencies. Analysts have provided a mean price target of 36,000 KRW, with a median of 36,000 KRW, indicating a neutral outlook. The mean recommendation of 1.50 (on a scale from 1 to 5) suggests a slight bias toward a buy rating, but the absence of hold or strong sell ratings indicates a relatively optimistic sentiment. Risk factors for I Sens Inc include liquidity concerns, as the company's net cash is negative after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not disclosed any recent equity offerings or dilutive events, and its shares outstanding have remained stable. Recent events include the publication of the latest financial results, which show a significant net loss despite positive operating cash flow. The company has not disclosed any major strategic initiatives or regulatory changes that would impact its operations. Analysts have not issued any new reports or transcripts in the recent period, and there are no notable earnings surprises or management statements to highlight.